logo

Nuvasive, Inc. (NUVA)



Trade NUVA now with
  Date
  Headline
8/3/2022 4:14:40 PM NuVasive Q2 Loss/share $0.02 Vs. Profit $0.03 Year Ago
5/4/2022 4:30:29 PM NuVasive Lifts FY22 Outlook
5/4/2022 4:14:35 PM NuVasive, Inc. (NUVA) Has Raised Its 2022 EPS Estimate To 2.15 - 2.45 From 2.05 - 2.35
5/4/2022 4:11:05 PM NuVasive Q1 EPS $0.35 Vs. Loss $0.15 Year Ago
2/23/2022 4:25:23 PM NuVasive Reports Q4 Loss Per Share Of $0.71 Vs. EPS Of $0.03 Last Year
2/23/2022 4:18:23 PM NuVasive, Inc. Q4 Earnings Summary
1/31/2022 4:11:50 PM NuVasive Appoints Andrew Morton As Chief Human Resources Officer
1/5/2022 7:02:19 AM NuVasive Gets FDA Clearance For Expanded Indications Of Use For Attrax Putty With Thoracolumbar Interbody Portfolio
11/9/2021 4:18:59 PM NuVasive, Inc. (NUVA) Has Raised Its 2021 EPS Estimate To 1.73 - 1.83 From 2.25 - 2.35
11/9/2021 4:18:13 PM NuVasive, Inc. (NUVA) Has Raised Its 2021 Revenue Estimate To $1.132 - $1.142 Bln From $1.190 - $1.210 Bln